Form 4: Immunovant Executive Jay S. Stout Reports Stock and Option Awards

Jay S. Stout, Chief Technology Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• Jay S. Stout, the Chief Technology Officer of Immunovant, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On April 2, 2024, Stout acquired 54,978 shares of common stock in the form of restricted stock units (RSUs) and disposed of 0 shares.
• These RSUs were granted under the company's 2019 Equity Incentive Plan and represent a contingent right to receive one share of common stock per unit upon vesting.
• The RSUs vest as to 25% on April 2, 2025, and the remaining units vest in substantially equal quarterly installments over three years, contingent upon continued service.
• Stout also acquired options to purchase 68,723 shares of common stock at an exercise price of $30.78 on April 2, 2024.
• These options also vest as to 25% on April 2, 2025, with the remainder vesting in 36 substantially equal monthly installments over three years, subject to continued service.
• Following these transactions, Stout directly owns 154,978 shares of Immunovant common stock and options to purchase 68,723 shares.
• The options expire on April 2, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grants are standard practice and incentivize management, which is generally viewed favorably. There are no indications of negative news or concerns.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders, incentivizing long-term performance.
• The vesting schedules encourage continued service and commitment to the company over the next three years.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Stock option and RSU grants are common practices in the biotechnology industry to attract, retain, and incentivize key personnel. These grants align executive compensation with company performance and shareholder value.

Comparison to Industry Standards

• Equity compensation packages for CTOs in biotech companies of Immunovant's size typically include a mix of stock options and restricted stock units.
• Vesting schedules of 3-4 years are standard in the industry to ensure long-term commitment.
• The specific value of the grants would need to be compared against peer companies to determine if it is above, below, or in line with industry averages.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates